Global Recombinant Plasma Protein Therapeutics Market: Industry Analysis and Forecast (2019-2026) – By Drug Class, Cell Line, Indication and Region

Global Recombinant Plasma Protein Therapeutics Market is expected to grow at a CAGR of 5.3% during the forecast period and market is expected to reach US$ 17.3 Bn. by 2026. Plasma-derived therapies and their recombinant analogs, collectively referred to plasma protein therapies, biologic medicines, and chemical medicines, because production begins with plasma as a biological starting material. Each therapy has its unique biochemical profile, which effects in different clinical responses and efficiency among patients. A numeral of plasma proteins is also produced using recombinant gene technologies, in which the protein is produced from an expression system into which a gene has been presented. Global Recombinant Plasma Protein Therapeutics Market To know about the Research Methodology :- Request Free Sample Report The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The global recombinant plasma protein therapeutics market primary is driven by various factors such as change from use of plasma-derived proteins to recombinant therapies. Furthermore, increase in the amount of healthcare providers prescribing recombinant plasma protein therapies for hemophilia A and rapid implementation of genetic causing technologies in healthcare for the development of new therapeutics are also estimated to fuel the market. However, the high cost of treatment and availability of different therapies are expected to restrain the global market. Furthermore, an increase in the investment in research and technology is measured as a major opportunity for the growth of the global recombinant plasma protein therapeutics market. Global Recombinant Plasma Protein Therapeutics Market The report covers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a significant role in the enlargement of the market from 2019 to 2026. Based on the drug class, the recombinant coagulation factor VIII segment expected to dominate the XX% market share during the forecast period. It has completely replaced human blood plasma-derived proteins and desmopressin in treating a severe and mild form of hemophilia A. Improvements in recombinant technology coagulation factor VIII are organization a platform for novel therapeutic possibilities in patients with hemophilia. The development of turoctocog alfa, third-generation, B-domain truncated recombinant FVIII, has been produced and formulated without the use of human serum-derived components. By Indication the, hemophilia A segment is held to dominate the XX% market share during the forecast period. High prevalence rate and occurrence of simple form in 70% detected patient’s purposes of its market. Hemophilia A can be mild, moderate, depending on how little you have of factor VIII. Regionally, North America is expected to account for the largest share of the recombinant plasma protein therapeutics market during the forecast period. The major factors influencing its market growth are the rising prevalence of hemophilia A and the existence of a comprehensive network of federally funded hemophilia treatment centers. North America controlled the market owing to the presence of a large patient base and availability of well-developed infrastructure for storing and maintaining high-quality source plasma are major factors dynamic the growth of the market. The objective of the report is to present comprehensive analysis of global Recombinant Plasma Protein Therapeutics market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global Recombinant Plasma Protein Therapeutics market dynamics, structure by analyzing the market segments, and project the global Recombinant Plasma Protein Therapeutics market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global Recombinant Plasma Protein Therapeutics market make the report investor’s guide.

Scope of the Global Recombinant Plasma Protein Therapeutics Market: Inquire before buying

Global Recombinant Plasma Protein Therapeutics Market, By Drug Class

• Recombinant Coagulation Factors o Recombinant Coagulation Factor VIII o Recombinant Coagulation Factor IX o Recombinant Coagulation Factor VIIa o Others • Human C1 Esterase Inhibitor

Global Recombinant Plasma Protein Therapeutics Market, By Cell Line

• Chinese Hamster Ovary (CHO) Cell Line • Baby Hamster Kidney (BHK) Cell Line • Human Embryonic Kidney (HEK) Cell Line • Others

Global Recombinant Plasma Protein Therapeutics Market, By Indication

• Hemophilia A • Hemophilia B • Von Willebrand Disease • Others

Global Recombinant Plasma Protein Therapeutics Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Recombinant Plasma Protein Therapeutics Market

• CSL Limited • Shire Takeda Pharmaceutical Company Limited • Octapharma • Novo Nordisk A/S • Bayer AG • Bioverativ Therapeutics • Aptevo Therapeutics • Pharming Group NV • Pfizer Inc. • Ferring B.V. • Baxter • HEMA Biologics, LLC • OPKO Health, Inc • Sinocelltech Ltd
Global Recombinant Plasma Protein Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Recombinant Plasma Protein Therapeutics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast 6.1. Global Recombinant Plasma Protein Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class 7.4. Global Recombinant Plasma Protein Therapeutics Market Size (US$ Bn) Forecast, by Drug Class 7.5. Global Recombinant Plasma Protein Therapeutics Market Analysis, by Drug Class 7.6. Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class 8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line 8.4. Global Recombinant Plasma Protein Therapeutics Market Size (US$ Bn) Forecast, by Cell Line 8.5. Global Recombinant Plasma Protein Therapeutics Market Analysis, by Cell Line 8.6. Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line 9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication 9.4. Global Recombinant Plasma Protein Therapeutics Market Size (US$ Bn) Forecast, by Indication 9.5. Global Recombinant Plasma Protein Therapeutics Market Analysis, by Indication 9.6. Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication 10. Global Recombinant Plasma Protein Therapeutics Market Analysis, by Region 10.1. Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Region 10.2. Global Recombinant Plasma Protein Therapeutics Market Size (US$ Bn) Forecast, by Region 10.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Region 11. North America Recombinant Plasma Protein Therapeutics Market Analysis 11.1. Key Findings 11.2. North America Recombinant Plasma Protein Therapeutics Market Overview 11.3. North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class 11.4. North America Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 11.4.1. Recombinant Coagulation Factors 11.4.1.1. Recombinant Coagulation Factor VIII 11.4.1.2. Recombinant Coagulation Factor IX 11.4.1.3. Recombinant Coagulation Factor VIIa 11.4.1.4. Others 11.4.2. Human C1 Esterase Inhibitor 11.5. North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line 11.6. North America Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 11.6.1. Chinese Hamster Ovary (CHO) Cell Line 11.6.2. Baby Hamster Kidney (BHK) Cell Line 11.6.3. Human Embryonic Kidney (HEK) Cell Line 11.6.4. Others 11.7. North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication 11.8. North America Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 11.8.1. Hemophilia A 11.8.2. Hemophilia B 11.8.3. Von Willebrand Disease 11.8.4. Others 11.9. North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country 11.10. North America Recombinant Plasma Protein Therapeutics Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Recombinant Plasma Protein Therapeutics Market Analysis, by Country 11.12. U.S. Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 11.12.1. Recombinant Coagulation Factors 11.12.1.1. Recombinant Coagulation Factor VIII 11.12.1.2. Recombinant Coagulation Factor IX 11.12.1.3. Recombinant Coagulation Factor VIIa 11.12.1.4. Others 11.12.2. Human C1 Esterase Inhibitor 11.13. U.S. Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 11.13.1. Chinese Hamster Ovary (CHO) Cell Line 11.13.2. Baby Hamster Kidney (BHK) Cell Line 11.13.3. Human Embryonic Kidney (HEK) Cell Line 11.13.4. Others 11.14. U.S. Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 11.14.1. Hemophilia A 11.14.2. Hemophilia B 11.14.3. Von Willebrand Disease 11.14.4. Others 11.15. Canada Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 11.15.1. Recombinant Coagulation Factors 11.15.1.1. Recombinant Coagulation Factor VIII 11.15.1.2. Recombinant Coagulation Factor IX 11.15.1.3. Recombinant Coagulation Factor VIIa 11.15.1.4. Others 11.15.2. Human C1 Esterase Inhibitor 11.16. Canada Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 11.16.1. Chinese Hamster Ovary (CHO) Cell Line 11.16.2. Baby Hamster Kidney (BHK) Cell Line 11.16.3. Human Embryonic Kidney (HEK) Cell Line 11.16.4. Others 11.17. Canada Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 11.17.1. Hemophilia A 11.17.2. Hemophilia B 11.17.3. Von Willebrand Disease 11.17.4. Others 11.18. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Cell Line 11.18.3. By Indication 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Recombinant Plasma Protein Therapeutics Market Analysis 12.1. Key Findings 12.2. Europe Recombinant Plasma Protein Therapeutics Market Overview 12.3. Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class 12.4. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 12.4.1. Recombinant Coagulation Factors 12.4.1.1. Recombinant Coagulation Factor VIII 12.4.1.2. Recombinant Coagulation Factor IX 12.4.1.3. Recombinant Coagulation Factor VIIa 12.4.1.4. Others 12.4.2. Human C1 Esterase Inhibitor 12.5. Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line 12.6. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 12.6.1. Chinese Hamster Ovary (CHO) Cell Line 12.6.2. Baby Hamster Kidney (BHK) Cell Line 12.6.3. Human Embryonic Kidney (HEK) Cell Line 12.6.4. Others 12.7. Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication 12.8. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 12.8.1. Hemophilia A 12.8.2. Hemophilia B 12.8.3. Von Willebrand Disease 12.8.4. Others 12.9. Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country 12.10. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Recombinant Plasma Protein Therapeutics Market Analysis, by Country 12.12. Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 12.12.1. Recombinant Coagulation Factors 12.12.1.1. Recombinant Coagulation Factor VIII 12.12.1.2. Recombinant Coagulation Factor IX 12.12.1.3. Recombinant Coagulation Factor VIIa 12.12.1.4. Others 12.12.2. Human C1 Esterase Inhibitor 12.13. Germany Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 12.13.1. Chinese Hamster Ovary (CHO) Cell Line 12.13.2. Baby Hamster Kidney (BHK) Cell Line 12.13.3. Human Embryonic Kidney (HEK) Cell Line 12.13.4. Others 12.14. Germany Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 12.14.1. Hemophilia A 12.14.2. Hemophilia B 12.14.3. Von Willebrand Disease 12.14.4. Others 12.15. U.K. Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 12.15.1. Recombinant Coagulation Factors 12.15.1.1. Recombinant Coagulation Factor VIII 12.15.1.2. Recombinant Coagulation Factor IX 12.15.1.3. Recombinant Coagulation Factor VIIa 12.15.1.4. Others 12.15.2. Human C1 Esterase Inhibitor 12.16. U.K. Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 12.16.1. Chinese Hamster Ovary (CHO) Cell Line 12.16.2. Baby Hamster Kidney (BHK) Cell Line 12.16.3. Human Embryonic Kidney (HEK) Cell Line 12.16.4. Others 12.17. U.K. Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 12.17.1. Hemophilia A 12.17.2. Hemophilia B 12.17.3. Von Willebrand Disease 12.17.4. Others 12.18. France Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 12.18.1. Recombinant Coagulation Factors 12.18.1.1. Recombinant Coagulation Factor VIII 12.18.1.2. Recombinant Coagulation Factor IX 12.18.1.3. Recombinant Coagulation Factor VIIa 12.18.1.4. Others 12.18.2. Human C1 Esterase Inhibitor 12.19. France Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 12.19.1. Chinese Hamster Ovary (CHO) Cell Line 12.19.2. Baby Hamster Kidney (BHK) Cell Line 12.19.3. Human Embryonic Kidney (HEK) Cell Line 12.19.4. Others 12.20. France Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 12.20.1. Hemophilia A 12.20.2. Hemophilia B 12.20.3. Von Willebrand Disease 12.20.4. Others 12.21. Italy Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 12.21.1. Recombinant Coagulation Factors 12.21.1.1. Recombinant Coagulation Factor VIII 12.21.1.2. Recombinant Coagulation Factor IX 12.21.1.3. Recombinant Coagulation Factor VIIa 12.21.1.4. Others 12.21.2. Human C1 Esterase Inhibitor 12.22. Italy Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 12.22.1. Chinese Hamster Ovary (CHO) Cell Line 12.22.2. Baby Hamster Kidney (BHK) Cell Line 12.22.3. Human Embryonic Kidney (HEK) Cell Line 12.22.4. Others 12.23. Italy Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 12.23.1. Hemophilia A 12.23.2. Hemophilia B 12.23.3. Von Willebrand Disease 12.23.4. Others 12.24. Spain Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 12.24.1. Recombinant Coagulation Factors 12.24.1.1. Recombinant Coagulation Factor VIII 12.24.1.2. Recombinant Coagulation Factor IX 12.24.1.3. Recombinant Coagulation Factor VIIa 12.24.1.4. Others 12.24.2. Human C1 Esterase Inhibitor 12.25. Spain Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 12.25.1. Chinese Hamster Ovary (CHO) Cell Line 12.25.2. Baby Hamster Kidney (BHK) Cell Line 12.25.3. Human Embryonic Kidney (HEK) Cell Line 12.25.4. Others 12.26. Spain Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 12.26.1. Hemophilia A 12.26.2. Hemophilia B 12.26.3. Von Willebrand Disease 12.26.4. Others 12.27. Rest of Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 12.27.1. Recombinant Coagulation Factors 12.27.1.1. Recombinant Coagulation Factor VIII 12.27.1.2. Recombinant Coagulation Factor IX 12.27.1.3. Recombinant Coagulation Factor VIIa 12.27.1.4. Others 12.27.2. Human C1 Esterase Inhibitor 12.28. Rest of Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 12.28.1. Chinese Hamster Ovary (CHO) Cell Line 12.28.2. Baby Hamster Kidney (BHK) Cell Line 12.28.3. Human Embryonic Kidney (HEK) Cell Line 12.28.4. Others 12.29. Rest Of Europe Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 12.29.1. Hemophilia A 12.29.2. Hemophilia B 12.29.3. Von Willebrand Disease 12.29.4. Others 12.30. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Cell Line 12.30.3. By Indication 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis 13.1. Key Findings 13.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Overview 13.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class 13.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 13.4.1. Recombinant Coagulation Factors 13.4.1.1. Recombinant Coagulation Factor VIII 13.4.1.2. Recombinant Coagulation Factor IX 13.4.1.3. Recombinant Coagulation Factor VIIa 13.4.1.4. Others 13.4.2. Human C1 Esterase Inhibitor 13.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, By Cell Line 13.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 13.6.1. Chinese Hamster Ovary (CHO) Cell Line 13.6.2. Baby Hamster Kidney (BHK) Cell Line 13.6.3. Human Embryonic Kidney (HEK) Cell Line 13.6.4. Others 13.7. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication 13.8. Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 13.8.1. Hemophilia A 13.8.2. Hemophilia B 13.8.3. Von Willebrand Disease 13.8.4. Others 13.9. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country 13.10. Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis, by Country 13.12. China Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 13.12.1. Recombinant Coagulation Factors 13.12.1.1. Recombinant Coagulation Factor VIII 13.12.1.2. Recombinant Coagulation Factor IX 13.12.1.3. Recombinant Coagulation Factor VIIa 13.12.1.4. Others 13.12.2. Human C1 Esterase Inhibitor 13.13. China Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 13.13.1. Chinese Hamster Ovary (CHO) Cell Line 13.13.2. Baby Hamster Kidney (BHK) Cell Line 13.13.3. Human Embryonic Kidney (HEK) Cell Line 13.13.4. Others 13.14. China Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 13.14.1. Hemophilia A 13.14.2. Hemophilia B 13.14.3. Von Willebrand Disease 13.14.4. Others 13.15. India Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 13.15.1. Recombinant Coagulation Factors 13.15.1.1. Recombinant Coagulation Factor VIII 13.15.1.2. Recombinant Coagulation Factor IX 13.15.1.3. Recombinant Coagulation Factor VIIa 13.15.1.4. Others 13.15.2. Human C1 Esterase Inhibitor 13.16. India Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 13.16.1. Chinese Hamster Ovary (CHO) Cell Line 13.16.2. Baby Hamster Kidney (BHK) Cell Line 13.16.3. Human Embryonic Kidney (HEK) Cell Line 13.16.4. Others 13.17. India Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 13.17.1. Hemophilia A 13.17.2. Hemophilia B 13.17.3. Von Willebrand Disease 13.17.4. Others 13.18. Japan Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 13.18.1. Recombinant Coagulation Factors 13.18.1.1. Recombinant Coagulation Factor VIII 13.18.1.2. Recombinant Coagulation Factor IX 13.18.1.3. Recombinant Coagulation Factor VIIa 13.18.1.4. Others 13.18.2. Human C1 Esterase Inhibitor 13.19. Japan Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 13.19.1. Chinese Hamster Ovary (CHO) Cell Line 13.19.2. Baby Hamster Kidney (BHK) Cell Line 13.19.3. Human Embryonic Kidney (HEK) Cell Line 13.19.4. Others 13.20. Japan Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 13.20.1. Hemophilia A 13.20.2. Hemophilia B 13.20.3. Von Willebrand Disease 13.20.4. Others 13.21. ASEAN Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 13.21.1. Recombinant Coagulation Factors 13.21.1.1. Recombinant Coagulation Factor VIII 13.21.1.2. Recombinant Coagulation Factor IX 13.21.1.3. Recombinant Coagulation Factor VIIa 13.21.1.4. Others 13.21.2. Human C1 Esterase Inhibitor 13.22. ASEAN Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 13.22.1. Chinese Hamster Ovary (CHO) Cell Line 13.22.2. Baby Hamster Kidney (BHK) Cell Line 13.22.3. Human Embryonic Kidney (HEK) Cell Line 13.22.4. Others 13.23. ASEAN Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 13.23.1. Hemophilia A 13.23.2. Hemophilia B 13.23.3. Von Willebrand Disease 13.23.4. Others 13.24. Rest of Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 13.24.1. Recombinant Coagulation Factors 13.24.1.1. Recombinant Coagulation Factor VIII 13.24.1.2. Recombinant Coagulation Factor IX 13.24.1.3. Recombinant Coagulation Factor VIIa 13.24.1.4. Others 13.24.2. Human C1 Esterase Inhibitor 13.25. Rest of Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 13.25.1. Chinese Hamster Ovary (CHO) Cell Line 13.25.2. Baby Hamster Kidney (BHK) Cell Line 13.25.3. Human Embryonic Kidney (HEK) Cell Line 13.25.4. Others 13.26. Rest of Asia Pacific Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 13.26.1. Hemophilia A 13.26.2. Hemophilia B 13.26.3. Von Willebrand Disease 13.26.4. Others 13.27. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Cell Line 13.27.3. By Indication 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Overview 14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class 14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 14.4.1. Recombinant Coagulation Factors 14.4.1.1. Recombinant Coagulation Factor VIII 14.4.1.2. Recombinant Coagulation Factor IX 14.4.1.3. Recombinant Coagulation Factor VIIa 14.4.1.4. Others 14.4.2. Human C1 Esterase Inhibitor 14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, By Cell Line 14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 14.6.1. Chinese Hamster Ovary (CHO) Cell Line 14.6.2. Baby Hamster Kidney (BHK) Cell Line 14.6.3. Human Embryonic Kidney (HEK) Cell Line 14.6.4. Others 14.7. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication 14.8. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 14.8.1. Hemophilia A 14.8.2. Hemophilia B 14.8.3. Von Willebrand Disease 14.8.4. Others 14.9. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country 14.10. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis, by Country 14.12. GCC Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 14.12.1. Recombinant Coagulation Factors 14.12.1.1. Recombinant Coagulation Factor VIII 14.12.1.2. Recombinant Coagulation Factor IX 14.12.1.3. Recombinant Coagulation Factor VIIa 14.12.1.4. Others 14.12.2. Human C1 Esterase Inhibitor 14.13. GCC Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 14.13.1. Chinese Hamster Ovary (CHO) Cell Line 14.13.2. Baby Hamster Kidney (BHK) Cell Line 14.13.3. Human Embryonic Kidney (HEK) Cell Line 14.13.4. Others 14.14. GCC Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 14.14.1. Hemophilia A 14.14.2. Hemophilia B 14.14.3. Von Willebrand Disease 14.14.4. Others 14.15. South Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 14.15.1. Recombinant Coagulation Factors 14.15.1.1. Recombinant Coagulation Factor VIII 14.15.1.2. Recombinant Coagulation Factor IX 14.15.1.3. Recombinant Coagulation Factor VIIa 14.15.1.4. Others 14.15.2. Human C1 Esterase Inhibitor 14.16. South Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 14.16.1. Chinese Hamster Ovary (CHO) Cell Line 14.16.2. Baby Hamster Kidney (BHK) Cell Line 14.16.3. Human Embryonic Kidney (HEK) Cell Line 14.16.4. Others 14.17. South Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 14.17.1. Hemophilia A 14.17.2. Hemophilia B 14.17.3. Von Willebrand Disease 14.17.4. Others 14.18. Rest of Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 14.18.1. Recombinant Coagulation Factors 14.18.1.1. Recombinant Coagulation Factor VIII 14.18.1.2. Recombinant Coagulation Factor IX 14.18.1.3. Recombinant Coagulation Factor VIIa 14.18.1.4. Others 14.18.2. Human C1 Esterase Inhibitor 14.19. Rest of Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 14.19.1. Chinese Hamster Ovary (CHO) Cell Line 14.19.2. Baby Hamster Kidney (BHK) Cell Line 14.19.3. Human Embryonic Kidney (HEK) Cell Line 14.19.4. Others 14.20. Rest of Middle East & Africa Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 14.20.1. Hemophilia A 14.20.2. Hemophilia B 14.20.3. Von Willebrand Disease 14.20.4. Others 14.21. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 14.21.1.1. By Drug Class 14.21.1.2. By Cell Line 14.21.1.3. By Indication 14.21.1.4. PEST Analysis 14.21.1.5. Key Trends 14.21.1.6. Key Developments 15. South America Recombinant Plasma Protein Therapeutics Market Analysis 15.1. Key Findings 15.2. South America Recombinant Plasma Protein Therapeutics Market Overview 15.3. South America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class 15.4. South America Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 15.4.1. Recombinant Coagulation Factors 15.4.1.1. Recombinant Coagulation Factor VIII 15.4.1.2. Recombinant Coagulation Factor IX 15.4.1.3. Recombinant Coagulation Factor VIIa 15.4.1.4. Others 15.4.2. Human C1 Esterase Inhibitor 15.5. South America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, By Cell Line 15.6. South America Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 15.6.1. Chinese Hamster Ovary (CHO) Cell Line 15.6.2. Baby Hamster Kidney (BHK) Cell Line 15.6.3. Human Embryonic Kidney (HEK) Cell Line 15.6.4. Others 15.7. South America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication 15.8. South America Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 15.8.1. Hemophilia A 15.8.2. Hemophilia B 15.8.3. Von Willebrand Disease 15.8.4. Others 15.9. South America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country 15.10. South America Recombinant Plasma Protein Therapeutics Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Recombinant Plasma Protein Therapeutics Market Analysis, by Country 15.12. Brazil Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 15.12.1. Recombinant Coagulation Factors 15.12.1.1. Recombinant Coagulation Factor VIII 15.12.1.2. Recombinant Coagulation Factor IX 15.12.1.3. Recombinant Coagulation Factor VIIa 15.12.1.4. Others 15.12.2. Human C1 Esterase Inhibitor 15.13. Brazil Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 15.13.1. Chinese Hamster Ovary (CHO) Cell Line 15.13.2. Baby Hamster Kidney (BHK) Cell Line 15.13.3. Human Embryonic Kidney (HEK) Cell Line 15.13.4. Others 15.14. Brazil Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 15.14.1. Hemophilia A 15.14.2. Hemophilia B 15.14.3. Von Willebrand Disease 15.14.4. Others 15.15. Mexico Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 15.15.1. Recombinant Coagulation Factors 15.15.1.1. Recombinant Coagulation Factor VIII 15.15.1.2. Recombinant Coagulation Factor IX 15.15.1.3. Recombinant Coagulation Factor VIIa 15.15.1.4. Others 15.15.2. Human C1 Esterase Inhibitor 15.16. Mexico Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 15.16.1. Chinese Hamster Ovary (CHO) Cell Line 15.16.2. Baby Hamster Kidney (BHK) Cell Line 15.16.3. Human Embryonic Kidney (HEK) Cell Line 15.16.4. Others 15.17. Mexico Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 15.17.1. Hemophilia A 15.17.2. Hemophilia B 15.17.3. Von Willebrand Disease 15.17.4. Others 15.18. Rest of South America Recombinant Plasma Protein Therapeutics Market Forecast, by Drug Class 15.18.1. Recombinant Coagulation Factors 15.18.1.1. Recombinant Coagulation Factor VIII 15.18.1.2. Recombinant Coagulation Factor IX 15.18.1.3. Recombinant Coagulation Factor VIIa 15.18.1.4. Others 15.18.2. Human C1 Esterase Inhibitor 15.19. Rest of South America Recombinant Plasma Protein Therapeutics Market Forecast, by Cell Line 15.19.1. Chinese Hamster Ovary (CHO) Cell Line 15.19.2. Baby Hamster Kidney (BHK) Cell Line 15.19.3. Human Embryonic Kidney (HEK) Cell Line 15.19.4. Others 15.20. Rest of South America Recombinant Plasma Protein Therapeutics Market Forecast, by Indication 15.20.1. Hemophilia A 15.20.2. Hemophilia B 15.20.3. Von Willebrand Disease 15.20.4. Others 15.21. South America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Cell Line 15.21.3. By Indication 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. CSL Limited 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Shire Takeda Pharmaceutical Company Limited 16.3.3. Octapharma 16.3.4. Novo Nordisk A/S 16.3.5. Bayer AG 16.3.6. Bioverativ Therapeutics 16.3.7. Aptevo Therapeutics 16.3.8. Pharming Group NV 16.3.9. Pfizer Inc. 16.3.10. Ferring B.V. 16.3.11. Baxter 16.3.12. HEMA Biologics, LLC 16.3.13. OPKO Health, Inc 16.3.14. Sinocelltech Ltd 17. Primary Key Insights

About This Report

Report ID 36227
Category Healthcare
Published Date Nov 2019
Updated Date Aug 2020
Contact Us